What do we do now that the long-acting growth hormone is here?

What do we do now that the long-acting growth hormone is here?

In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone deficiency (PGHD).Lonapegsomatropin, a long-acting...

Full description

Bibliographic Details
Main Author: Bradley S. Miller
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Endocrinology
Subjects:
long-acting growth hormone
pediatric growth hormone deficiency
lonapegsomatropin
somapacitan
somatrogon
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.980979/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.980979/full

Similar Items